49 results
Page 2 of 3
F-3/A
errhz2y
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
ghdogm0ui7vwzpio97l
10 Jun 22
Current report (foreign)
6:05am
F-3/A
n0eb7c3071wk44 ny64
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
am0wwj
5 May 22
Current report (foreign)
6:04am
6-K
s1fskjkh3ytpx
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
ltahschkaqndc
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
EX-1.2
9w40srsdwes oaroyt
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
orbbic pfm
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
vohnx
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
fwg1uoex
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
osito tovs
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
ikd610vr4nskak 26v28
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
n9ba0j tx
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
ijyg59u3 z6zn4vu5924
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
mnus13un c3k
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
EX-99.3
s0n8o pr1c16ekg
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
iok829oas7l3o4bui
27 Aug 21
Current report (foreign)
4:10pm
6-K
EX-99.1
8wrtioys
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
3xqmhelcgtntk9
17 May 21
Connect Biopharma Announces First
5:27pm
424B4
c1jfufybig5n2mwm
19 Mar 21
Prospectus supplement with pricing info
4:49pm